Bulaşıcı Hastalıklarla Mücadele Etmekte İnovatif Sağlık Teknolojilerinin Rolü
Özet
Bulaşıcı hastalıklarla mücadele, nüfus artışı ve küresel hareketlilik nedeniyle dijitalleşen tanı ve tedavi yöntemlerine olan ihtiyacı artırmıştır. Yapay zeka, nükleik asit amplifikasyon testleri (NAAT), yeni nesil dizileme (NGS) ve CRISPR tabanlı sistemler gibi yenilikçi teknolojiler, hastalıkların teşhis süresini kısaltırken doğruluğu en üst düzeye çıkarmaktadır. Mobil sağlık uygulamaları ve matematiksel modellemeler sürveyans çalışmalarını güçlendirirken, mRNA aşı teknolojileri ve 3-D biyoyazıcılar gibi gelişmeler tedavi süreçlerinde devrim niteliğinde çözümler sunmaktadır. Bu teknolojik inovasyonların sağlık sistemlerine entegre edilmesi ve adil erişimin sağlanması, gelecekteki küresel salgınların önlenmesinde kritik bir rol oynamaktadır.
Infectious disease management has accelerated the need for digitized diagnostic and treatment methods due to population growth and global mobility. Innovative technologies such as artificial intelligence, nucleic acid amplification tests (NAAT), next-generation sequencing (NGS), and CRISPR-based systems minimize diagnosis times while maximizing accuracy. While mobile health applications and mathematical modeling strengthen surveillance efforts, advancements like mRNA vaccine technologies and 3-D bioprinters offer revolutionary solutions in treatment processes. Integrating these technological innovations into health systems and ensuring equitable access is critical for preventing future global pandemics.
Referanslar
Gray, J. (2015). Infection control: beyond the horizon. Journal of Hospital Infection, 89(4), 237-240.
Webster, A. (2002). Innovative health technologies and the social: redefining health, medicine and the body. Current sociology, 50(3), 443-457.
Sabat, A. J., Budimir, A., Nashev, D., Sá-Leão, R., Van Dijl, J. M., Laurent, F., ... & ESCMID Study Group of Epidemiological Markers (ESGEM. (2013). Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Eurosurveillance, 18(4), 20380.
Yuen K-S, Wang Z-M, Wong N-HM, Zhang Z-Q, Cheng T-F, Lui W-Y, et al. Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. Virus Res. 2018;244:296–303.
Chertow DS. Next-generation diagnostics with CRISPR. Science. 2018;360:381–2
Yang L, Güell M, Niu D, George H, Lesha E, Grishin D, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science. 2015;350:1101–4.
Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018;360:436–9.
Niu D, Wei H-J, Lin L, George H, Wang T, Lee I-H, et al. Inactivation of porcine endogenous retrovirus in pigs using CRISPRCas9. Science. 2017;357:1303–7.
Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ,Joung J, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356:438–42.
Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science. 2018;360:444–8.
Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38:870–4
Binnie, A., Fernandes, E., Almeida-Lousada, H., De Mello, R. A., & Castelo-Branco, P. (2021). CRISPR-based strategies in infectious disease diagnosis and therapy.
Kuşkucu, M. A. Mikrobiyoloji Ve İnfeksiyon Hastalıklarında Omikler Ve Uygulamaya Yansımaları ANKEM Derg 2013;27(Ek 2):95-100
Carbonnelle E, Mesquita C, Bile E et al. MALDITOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory, Clin Biochem 2011;44:(1):104-9.
Free, C., G. Phillips, L. Galli, L. Watson, L. Felix, P. Edwards, P. Patel and A. Haines. 2013. The eff ectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: A systematic review. PLoS Medicine 10(1):1–45. https://doi.org/ 10.1371/journal.pmed.1001362.
Nilsen, W., S. Kumar, A. Shar, C. Varoquiers, T. Wiley, W. T. Riley, M. Pavel, and A. A. Atienza. 2012. Advancing the Science of mHealth. Journal of Health Communication 17 Suppl 1:5-10. https://doi.org/10. 1080/10810730.2012.677394.
Adans-Dester, C. P., S. Bamberg, F. P. Bertacchi, B. Caulfi eld, K. Chappie, D. Demarchi, M. K. Erb, J. Estrada, E. E. Fabara, M. Freni, K. E. Friedl, R. Ghaffari, G. Gill, M. S. Greenberg, R. W. Hoyt, E. Jovanov, C. M. Kanzler, D. Katabi, M. Kernan, C. Kigin, S. I. 2020. Can mHealth Technology Help Mitigate the Eff ects of the COVID-19 Pandemic? IEEE Open Journal of Engineering in Medicine and Biology (1):243-248. https:// hdl.handle.net/1721.1/128713.
Blasimme, A., and E. Vayena. 2020. What’s Next for COVID-19 Apps? Governance and Oversight. Science 370(6518):760-762. https://doi.org/10.1126/ science.abd9006
Christaki, E. (2015). New technologies in predicting, preventing and controlling emerging infectious diseases. Virulence, 6(6), 558-565.
Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature 2008; 451:990-3; PMID:18288193; http://dx.doi.org/10.1038/ nature06536
Morse SS, Mazet JA, Woolhouse M, Parrish CR, Carroll D, Karesh WB, Zambrana-Torrelio C, Lipkin WI, Daszak P. Prediction and prevention of the next pandemic zoonosis. Lancet 2012; 380:1956-65; PMID:23200504; http://dx.doi.org/10.1016/S0140- 6736(12)61684-5
Khan K, Arino J, Hu W, Raposo P, Sears J, Calderon F, Heidebrecht C, Macdonald M, Liauw J, Chan A, et al. Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med 2009; 361:212-4; PMID:19564630; http://dx.doi.org/ 10.1056/NEJMc0904559
Colizza V, Barrat A, Barthelemy M, Vespignani A. Predictability and epidemic pathways in global outbreaks of infectious diseases: the SARS case study. BMC Med 2007; 5:34; PMID:18031574; http://dx. doi.org/10.1186/1741-7015-5-34
Polanco C, Castanon-Gonzalez JA, Macias AE, Samaniego JL, Buhse T, Villanueva-Martinez S. Detection of severe respiratory disease epidemic outbreaks by CUSUM-based overcrowd-severe-respiratory-diseaseindex model. Comput Math Methods Med 2013; 2013:213206; PMID:24069063; http://dx.doi.org/ 10.1155/2013/213206
Chin, C. S., Sorenson, J., Harris, J. B., Robins, W. P., Charles, R. C., Jean-Charles, R. R., ... & Waldor, M. K. (2011). The origin of the Haitian cholera outbreak strain. New England Journal of Medicine, 364(1), 33-42.
Henderson JP, Crowley JR, Pinkner JS et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli, PLoS Pathog 2009;5(2):e1000305. http://dx.doi.org/10.1371/journal.ppat.1000f305
Bengoechea JA. Infeciton systems biology: from ractive to proactive (P4) medicine, Int Microbiol 2012;15(2):55-60
Yang J, Yang Z, Lv H et al. Bridging HIV-1 Cellular Latency and Clinical Long-Term Non-Progressor: An Interactomic View, PLoS One 2013;8(2):e55791.
Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS ONE (2013) 8:e57755. 10.1371/journal.pone.0057755 [PMC free article]
Ramezanpour B, Haan I, Osterhaus A, Claassen E. Vector-based genetically modified vaccines: exploiting Jenner's legacy. Vaccine (2016) 34:6436–48. 10.1016/j.vaccine.2016.06.059
Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology (2018) 153:1–9. 10.1111/imm.12829
Weissman D, Pardi N, Muramatsu H, Kariko K. HPLC purification of in vitro transcribed long RNA. Methods Mol Biol. (2013) 969:43–54. 10.1007/978-1-62703-260-5_3
Kariko, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic acids research, 39(21), e142-e142.
Şengün, H. (2016). Sağlık hizmetleri sunumunda inovasyon. Med Bull Haseki, 54, 194-8.
